COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND CHEMOTHERAPEUTICS
The present invention pertains to anti-MIF antibodies, in particular their use in combination with therapeutics, i.e. chemotherapeutics, in the treatment of cancer.
1 . An anti-MIF antibody in combination with a chemotherapeutic agent for use in the treatment of cancer, wherein the chemotherapeutic agent is preferably gemcitabine, cisplatin and/or doxorubicin.
2 . The anti-MIF antibody in combination with chemotherapeutic agent according to claim 1 for use in the treatment of cancer, wherein the cancer is selected from the following group: pancreatic cancer, ovarian cancer, prostate cancer, breast cancer, lung cancer and colon cancer, more preferred pancreatic cancer, prostate cancer and ovarian cancer.
3 . The combination according to claim 1 or 2 wherein the anti-MIF antibody is selected from the following group: anti-MIF antibody RAM9, RAM0 and/or RAM4.
4 . The combination therapy according to any of claims 1 to 3 wherein the chemotherapeutic is gemcitabine.
5 . The combination therapy according to any of claims 1 to 4 , the anti-MIF antibody is RAM9, the chemotherapeutic is doxorubicin, optionally in combination with cisplatin and the cancer is ovarian cancer.
6 . The combination therapy according to any of claims 1 to 4 , the anti-MIF antibody is RAM9, the chemotherapeutic is gemcitabine and the cancer is pancreas carcinoma.
7 . The combination therapy according to any of claims 1 to 4 , the anti-MIF antibody is RAM0, the chemotherapeutic is doxorubicin, optionally in combination with cisplatin and the cancer is ovarian cancer.
8 . The combination therapy according to any of claims 1 to 4 , the anti-MIF antibody is RAM0, the chemotherapeutic is gemcitabine and the cancer is pancreas carcinoma.
9 . The combination therapy according to any of claims 1 to 4 , the anti-MIF antibody is RAM4, the chemotherapeutic is doxorubicin, optionally in combination with cisplatin and the cancer is ovarian cancer.
10 . The combination therapy according to any of claims 1 to 4 , the anti-MIF antibody is RAB4, the chemotherapeutic is gemcitabine, and the cancer is pancreas carcinoma.
11 . The combination therapy according to any of claims 1 to 4 , the anti-MIF antibody is RAM0, the chemotherapeutic is mitoxantrone, and the cancer is prostate cancer.
12 . A kit comprising the combination as defined in any of claims 1 to 11 above, and instructions for use.
13 . A combination as defined in any of claims 1 to 11 above, or the kit of claim 12 , for use in the treatment of cancer.